A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
Latest Information Update: 26 Mar 2024
At a glance
- Drugs CTX 130 (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms COBALT-LYM
- Sponsors CRISPR Therapeutics
- 20 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2022 According to a CRISPR Therapeutics media release, the company The Company continues to enroll and dose patients in the dose expansion part of the trial.
- 17 Jun 2022 Results (n=15; As of 6 Dec, 2021) assessing safety and efficacy of CTX130 in with relapsed/refractory T-cell malignancies, presented at the 27th Congress of the European Haematology Association.